MUMBAI, India, June 26 -- Intellectual Property India has published a patent application (202641072787 A) filed by Dr. Jai Shanker Pillai Hp; Ms. Bahast Aso Ali; Dr. Laishram Shantikumar Singh; Dr. Hersh Abdul; Dr. Chandrakala Linganna; and Ms. Sayantani Ghosh on June 12, 2026, for Ai-Integrated Microbial Strain Screening And Bioactive Compound Discovery Platform For Accelerated Drug Development.
Inventors include Dr. Jai Shanker Pillai Hp; Ms. Bahast Aso Ali; Dr. Laishram Shantikumar Singh; Dr. Hersh Abdul; Dr. Chandrakala Linganna; and Ms. Sayantani Ghosh.
The application for the patent was published on June 19, 2026, under issue no. 25/2026.
Abstract: The present invention discloses an AI-integrated microbial strain-based drug discovery platform configured for accelerated identification, screening, optimization, and validation of therapeutic compounds derived from microorganisms. The platform comprises a microbial acquisition module, adaptive culture optimization system, genomic sequencing engine, metabolomic profiling unit, AI-based bioactivity prediction engine, molecular docking framework, toxicity assessment module, automated high-throughput screening system, and cloud-connected collaborative database architecture. The invention utilizes artificial intelligence, machine learning, bioinformatics, and multi-omics integration to analyze microbial strains obtained from diverse environmental and biological sources for discovery of antibiotics, antiviral agents, anticancer compounds, anti-inflammatory molecules, and other bioactive metabolites. The adaptive cultivation system dynamically regulates environmental parameters to enhance metabolite production, while predictive analytics and molecular simulation frameworks evaluate therapeutic efficacy, safety, and pharmacokinetic characteristics of identified compounds. The invention further incorporates automated robotic screening systems, real-time analytical monitoring, and self-learning optimization mechanisms to improve discovery accuracy, reduce operational costs, minimize rediscovery of known compounds, and accelerate pharmaceutical development workflows for healthcare, biotechnology, industrial, and biomedical applications. Accompanied Drawing [FIGS. 1-2]
Disclaimer: Curated by HT Syndication.
